SCHEMBL2365781

SCHEMBL2365781

COCC1COC(=O)N1c1ccc(C(=O)N2CCNCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
SIGMAR1 Q99720 1/20 0.42
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B3 P37058 1/20 0.38
PIK3CA P42336 1/20 0.38
MGLL Q99685 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
GAA P10253 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365750 1.00 HPGD (0.43) HPGDSIGMAR1KMT2AMEN1ALDH1A1
SCHEMBL2366626 0.90 HPGD (0.42) HPGDSIGMAR1KMT2AMEN1ALDH1A1
SCHEMBL2366623 0.90 HPGD (0.42) HPGDSIGMAR1KMT2AMEN1ALDH1A1
SCHEMBL2365813 0.85 CPS1 (0.41) PIK3CAPARP1
SCHEMBL2365822 0.85 CPS1 (0.41) PIK3CAPARP1
SCHEMBL2366230 0.84 KDM1A (0.38) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL2366235 0.84 KDM1A (0.38) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL2366137 0.83 KMT2A (0.48) KMT2AMEN1ALDH1A1GAALMNA
SCHEMBL2366142 0.83 KMT2A (0.48) KMT2AMEN1ALDH1A1GAALMNA
SCHEMBL15015099 0.82 HPGD (0.48) HPGDSIGMAR1ALDH1A1HSD17B3MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 HPGD 135/4885SIGMAR1 4049/4885KMT2A 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.